Of note, only one of all 24 tumor samples with genomic MAPK alteration and none of the five BRAF V600E mutated tumors had been treated with MAPK directed targeted agents before surgery, which excludes an extrinsic therapy induced reduction of pERK levels in these cases. This evidence concerns the gene EIF2AK3 and neoplasm.